Trifluoroacetic acid → (S)-2-(2-methyl-3-(piperidin-3-ylamino)quinoxalin-5-yl)-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-one

Participants

Reaction Steps

Prepared according to Example 53, using tert-butyl (3S)-3-((3-methyl-8-(4-oxo-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-quinoxalinyl)amino)-1-piperidinecarboxylate (Ex. 51) and (2.5:1) DCM:TFA. Purification by reverse-phase preparative HPLC (Phenomenex Gemini column, 10 micron, C18, 100 Å, 150×30 mm, 0.1% TFA in ACN/H2O, gradient 5% to 80%) and free-base generation by elution of a solution of the product in MeOH through a pre-washed column of Si-carbonate (SiliaPrep, Silicyle) provided 2-(2-methyl-3-((3S)-3-piperidinylamino)-5-quinoxalinyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (105 mg, 44%). 1H NMR (CDCl3) δ: 7.87-7.95 (m, 1H), 7.59-7.67 (m, 1H), 7.31-7.42 (m, 1H), 7.09 (s, 1H), 5.29 (s, 1H), 4.06 (br. s., 1H), 3.59-3.66 (m, 2H), 3.20-3.28 (m, 1H), 2.84-3.06 (m, 5H), 2.59 (s, 3H), 2.15-2.33 (m, 2H), 2.03 (m, 2H), 1.73-1.85 (m, 1H), 1.51-1.69 (m, 1H). m/z (ESI, +ve) 377.2 (M+H)+.

Provenance & Evidence